Ventricular rate in atrial fibrillation and the risk of heart failure and death

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Ventricular rate in atrial fibrillation and the risk of heart failure and death. / Westergaard, Lucas Malta; Alhakak, Amna; Rørth, Rasmus; Fosbøl, Emil L.; Kristensen, Søren L.; Svendsen, Jesper H.; Graff, Claus; Nielsen, Jonas B.; Gislason, Gunnar H.; Kober, Lars; Torp-Pedersen, Christian; Lee, Christina J. Y.; Weeke, Peter E.

In: Europace, Vol. 25, No. 5, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Westergaard, LM, Alhakak, A, Rørth, R, Fosbøl, EL, Kristensen, SL, Svendsen, JH, Graff, C, Nielsen, JB, Gislason, GH, Kober, L, Torp-Pedersen, C, Lee, CJY & Weeke, PE 2023, 'Ventricular rate in atrial fibrillation and the risk of heart failure and death', Europace, vol. 25, no. 5. https://doi.org/10.1093/europace/euad088

APA

Westergaard, L. M., Alhakak, A., Rørth, R., Fosbøl, E. L., Kristensen, S. L., Svendsen, J. H., Graff, C., Nielsen, J. B., Gislason, G. H., Kober, L., Torp-Pedersen, C., Lee, C. J. Y., & Weeke, P. E. (2023). Ventricular rate in atrial fibrillation and the risk of heart failure and death. Europace, 25(5). https://doi.org/10.1093/europace/euad088

Vancouver

Westergaard LM, Alhakak A, Rørth R, Fosbøl EL, Kristensen SL, Svendsen JH et al. Ventricular rate in atrial fibrillation and the risk of heart failure and death. Europace. 2023;25(5). https://doi.org/10.1093/europace/euad088

Author

Westergaard, Lucas Malta ; Alhakak, Amna ; Rørth, Rasmus ; Fosbøl, Emil L. ; Kristensen, Søren L. ; Svendsen, Jesper H. ; Graff, Claus ; Nielsen, Jonas B. ; Gislason, Gunnar H. ; Kober, Lars ; Torp-Pedersen, Christian ; Lee, Christina J. Y. ; Weeke, Peter E. / Ventricular rate in atrial fibrillation and the risk of heart failure and death. In: Europace. 2023 ; Vol. 25, No. 5.

Bibtex

@article{f1af99b3eb714ec6bf9a4638c2f73396,
title = "Ventricular rate in atrial fibrillation and the risk of heart failure and death",
abstract = "Aims While clinical trials have suggested that a high ventricular rate is associated with increased risk of heart failure (HF) and mortality, all-comers studies are warranted. Objective To assess 1-year risk of new-onset diagnosed HF and all-cause mortality among rate-control treated patients presenting with atrial fibrillation (AF) on an electrocardiogram (ECG) according to ventricular rate. Methods and results ECGs recorded at the Copenhagen General Practitioners Laboratory (2001-15) were used to identify patients with AF. Multivariate Cox proportional hazard regression models were used to compare risk of new-onset HF and all-cause mortality after first ECG presenting with AF according to ventricular rate on ECG [ 110 beats per minute (bpm)]. We identified 7408 patients in treatment with rate control drugs at time of first ECG presenting with AF [median age 78 years (Q1,Q3 = 70-85 years)], 45.8% male, median ventricular rate 83 bpm, (Q1,Q3 = 71-101 bpm)]. During 1-year follow-up, 666 (9.0%) of all patients with AF developed HF and 858 (11.6%) died. Patients with AF ventricular rates 100-110 bpm and >110 bpm had a hazard ratio (HR) of 1.46 (CI: 1.10-1.95) and 2.41 (CI: 1.94-3.00) respectively for new-onset HF, compared with 60-79 bpm. Similarly, patients with AF ventricular rates 100-110 bpm and >110 bpm had a HR of 1.44 (CI: 1.13-1.82) and 1.34 (CI: 1.08-1.65) respectively for all-cause mortality, compared with 60-79 bpm. Conclusions Ventricular rates >= 100 bpm among patients presenting with AF on ECG in treatment with rate control drugs were associated with greater risk of both new-onset HF and all-cause mortality.",
keywords = "Atrial fibrillation, Atrial flutter, Rate-control, Heart failure, Mortality",
author = "Westergaard, {Lucas Malta} and Amna Alhakak and Rasmus R{\o}rth and Fosb{\o}l, {Emil L.} and Kristensen, {S{\o}ren L.} and Svendsen, {Jesper H.} and Claus Graff and Nielsen, {Jonas B.} and Gislason, {Gunnar H.} and Lars Kober and Christian Torp-Pedersen and Lee, {Christina J. Y.} and Weeke, {Peter E.}",
year = "2023",
doi = "10.1093/europace/euad088",
language = "English",
volume = "25",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Ventricular rate in atrial fibrillation and the risk of heart failure and death

AU - Westergaard, Lucas Malta

AU - Alhakak, Amna

AU - Rørth, Rasmus

AU - Fosbøl, Emil L.

AU - Kristensen, Søren L.

AU - Svendsen, Jesper H.

AU - Graff, Claus

AU - Nielsen, Jonas B.

AU - Gislason, Gunnar H.

AU - Kober, Lars

AU - Torp-Pedersen, Christian

AU - Lee, Christina J. Y.

AU - Weeke, Peter E.

PY - 2023

Y1 - 2023

N2 - Aims While clinical trials have suggested that a high ventricular rate is associated with increased risk of heart failure (HF) and mortality, all-comers studies are warranted. Objective To assess 1-year risk of new-onset diagnosed HF and all-cause mortality among rate-control treated patients presenting with atrial fibrillation (AF) on an electrocardiogram (ECG) according to ventricular rate. Methods and results ECGs recorded at the Copenhagen General Practitioners Laboratory (2001-15) were used to identify patients with AF. Multivariate Cox proportional hazard regression models were used to compare risk of new-onset HF and all-cause mortality after first ECG presenting with AF according to ventricular rate on ECG [ 110 beats per minute (bpm)]. We identified 7408 patients in treatment with rate control drugs at time of first ECG presenting with AF [median age 78 years (Q1,Q3 = 70-85 years)], 45.8% male, median ventricular rate 83 bpm, (Q1,Q3 = 71-101 bpm)]. During 1-year follow-up, 666 (9.0%) of all patients with AF developed HF and 858 (11.6%) died. Patients with AF ventricular rates 100-110 bpm and >110 bpm had a hazard ratio (HR) of 1.46 (CI: 1.10-1.95) and 2.41 (CI: 1.94-3.00) respectively for new-onset HF, compared with 60-79 bpm. Similarly, patients with AF ventricular rates 100-110 bpm and >110 bpm had a HR of 1.44 (CI: 1.13-1.82) and 1.34 (CI: 1.08-1.65) respectively for all-cause mortality, compared with 60-79 bpm. Conclusions Ventricular rates >= 100 bpm among patients presenting with AF on ECG in treatment with rate control drugs were associated with greater risk of both new-onset HF and all-cause mortality.

AB - Aims While clinical trials have suggested that a high ventricular rate is associated with increased risk of heart failure (HF) and mortality, all-comers studies are warranted. Objective To assess 1-year risk of new-onset diagnosed HF and all-cause mortality among rate-control treated patients presenting with atrial fibrillation (AF) on an electrocardiogram (ECG) according to ventricular rate. Methods and results ECGs recorded at the Copenhagen General Practitioners Laboratory (2001-15) were used to identify patients with AF. Multivariate Cox proportional hazard regression models were used to compare risk of new-onset HF and all-cause mortality after first ECG presenting with AF according to ventricular rate on ECG [ 110 beats per minute (bpm)]. We identified 7408 patients in treatment with rate control drugs at time of first ECG presenting with AF [median age 78 years (Q1,Q3 = 70-85 years)], 45.8% male, median ventricular rate 83 bpm, (Q1,Q3 = 71-101 bpm)]. During 1-year follow-up, 666 (9.0%) of all patients with AF developed HF and 858 (11.6%) died. Patients with AF ventricular rates 100-110 bpm and >110 bpm had a hazard ratio (HR) of 1.46 (CI: 1.10-1.95) and 2.41 (CI: 1.94-3.00) respectively for new-onset HF, compared with 60-79 bpm. Similarly, patients with AF ventricular rates 100-110 bpm and >110 bpm had a HR of 1.44 (CI: 1.13-1.82) and 1.34 (CI: 1.08-1.65) respectively for all-cause mortality, compared with 60-79 bpm. Conclusions Ventricular rates >= 100 bpm among patients presenting with AF on ECG in treatment with rate control drugs were associated with greater risk of both new-onset HF and all-cause mortality.

KW - Atrial fibrillation

KW - Atrial flutter

KW - Rate-control

KW - Heart failure

KW - Mortality

U2 - 10.1093/europace/euad088

DO - 10.1093/europace/euad088

M3 - Journal article

C2 - 37083042

VL - 25

JO - Europace

JF - Europace

SN - 1099-5129

IS - 5

ER -

ID: 346198809